Article Text

PDF
Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease
  1. C Mitea1,
  2. R Havenaar2,
  3. J Wouter Drijfhout1,
  4. L Edens3,
  5. L Dekking1,
  6. F Koning1
  1. 1
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
  2. 2
    TNO Quality of Life, Zeist, the Netherlands
  3. 3
    DSM Food Specialties, Delft, the Netherlands
  1. Dr E H A Dekking, Department of Immunohematology and Blood Transfusion, E3-Q, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; e.h.a.dekking{at}lumc.nl

Abstract

Background: Coeliac disease is caused by an immune response to gluten. As gluten proteins are proline rich they are resistant to enzymatic digestion in the gastrointestinal tract, a property that probably contributes to the immunogenic nature of gluten.

Aims: This study determined the efficiency of gluten degradation by a post-proline cutting enzyme, Aspergillus niger prolyl endoprotease (AN-PEP), in a dynamic system that closely mimics the human gastrointestinal tract (TIM system).

Methods: Two experiments were performed. In the first, a slice of bread was processed in the TIM system with and without co-administration of AN-PEP. In the second, a standard fast food menu was used. Samples of the digesting meals were taken from the stomach, duodenum, jejunum and ileum compartments at time zero until 4 hours after the start of the experiment. In these samples the levels of immunogenic peptides from gliadins and glutenins were assessed by monoclonal antibody-based competition assays, Western blot analysis and proliferation T-cell assays.

Results: AN-PEP accelerated the degradation of gluten in the stomach compartment to such an extent that hardly any gluten reached the duodenum compartment.

Conclusion: AN-PEP is capable of accelerating the degradation of gluten in a gastrointestinal system that closely mimics in-vivo digestion. This implies that the co-administration of AN-PEP with a gluten-containing meal might eliminate gluten toxicity, thus offering patients the possibility of abandoning (occasionally) their strict gluten-free diet.

Statistics from Altmetric.com

Footnotes

  • Funding: This study was supported by the Celiac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and partly funded by the Dutch Government (BSIK03009)

  • Competing interests: Declared (the declaration can be viewed on the Gut website at http://www.gutjnl.com/content/vol57/issue1).

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Emad M El-Omar